0JBU.L - Intellia Therapeutics, Inc.
| Chiusura precedente | 37,02 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 597 |
| Capitalizzazione | 18,126M |
| Beta (5 anni mensile) | 1,85 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,06 |
| Prossima data utili | 02 ago 2023 - 07 ago 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireIntellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday, June 12, at 8 a.m. ET CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the acceptance of a late-breaki
- GlobeNewswire
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedbackOn track to present additional clinical data in 2023 from both ongoing NTLA-2001
- GlobeNewswire
Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social and Governance (ESG) areas of focus. “As the leaders in a new era of medicine, we believe ES
- GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five
- GlobeNewswire
Intellia Therapeutics Names Bill Chase to its Board of Directors
CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of the audit committee and will succeed Caroline Dorsa as chair of the audit committee upon her retirement from the board. Ms. Dorsa is retiring from Intellia’
- GlobeNewswire
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed t
- GlobeNewswire
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAECAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND
- GlobeNewswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; global pivotal study initiation anticipated by year-end 2023On track to present additional clinical data in 2023
- GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726
- GlobeNewswire
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in people with hereditary angioedema (HAE) CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developin
- GlobeNewswire
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023P
- GlobeNewswire
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common
- GlobeNewswire
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public offering of $250 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock o
- GlobeNewswire
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002 NTLA-2002 was generally well-tolerated at all dose levels Intellia to host investor event to discuss updated data from Phase 1/2 study of NTLA-2002, its second systemicall
- GlobeNewswire
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both doses tested, with follow-up now reaching four to six monthsNTLA-2001 was generally well-tolerated CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading
- GlobeNewswire
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28; additional data to be presented in late-breaking, oral presentation at AHA on November 5Initiated dosing at 55 mg in Part 2 of the Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosisPresented interim data from the ongoing Phase 1/2 study of NTLA-2002, demonstr
- GlobeNewswire
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohortsCAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring new interim clinical data from
- GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financial results and operational highlights in a conference call on November 3, 2022, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately
- GlobeNewswire
Intellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October: Chardan’s 6th Annual Genetic Medicines Conference, New YorkDate: Monday, October 3, 2022Time: 8:30 a.m. ETFormat: Fireside chat 2022
- GlobeNewswire
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at investor event today, Friday, September 16, at 8:00 a.m. ET CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmace
- GlobeNewswire
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eightHAE attacks were reduced by 91% in the 25 mg dose cohort through week 16; two of three patients remain attack free since treatment with third patient attack free since week 10 through late
- GlobeNewswire
Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022
Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR reduction data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis CAMBRIDGE, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on deve
- GlobeNewswire
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA
- GlobeNewswire
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
First clinical data on safety and activity of NTLA-2002, Intellia’s second systemically administered in vivo CRISPR candidate CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring interim clinical data from the Phase 1/2 study of NTLA-2002 has been selected for an oral pres
- GlobeNewswire
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction data in 2H 2022 Presented updated interim data from the dose-escalation portion of the polyneuropathy arm, establishing deep reductions of disease-causing protein were sustained through 12 months following a single dose of NTLA-2001 Plans to present interim data for second in vivo CRISPR clinic